Stocks edged higher in afternoon trading Monday, with major indexes pushing deeper into record territory ahead of fresh economic updates this week. The Dow Jones Industrial Average added eight points, or 0.1%, to 17398. The S&P 500 index gained six points, or 0.3%, to 2024. Both indexes set new intraday records, placing them on track for new closing highs for the second straight session.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) earns a $5M milestone from GlaxoSmithKline (GSK -0.3%) for the designation of ISIS-GSK5rx as a development candidate for an undisclosed ocular disease. It is the second drug to be so identified in its collaboration with GSK. It earned a $1M milestone in July for a drug candidate to treat hepatitis B infection.

The Centers for Medicare and Medicaid Services (CMS) assigns a new reimbursement code to Alliqua Inc. (NASDAQ:ALQA)Biovance Human Amniotic Membrane Allograft, Q4154, that applies to products used outside of a physician's office. The code, categorized as Level II, expands reimbursement in the outpatient setting and complements the Level 1 reimbursement code already in place.

Mesa Laboratories, Inc.(NASDAQ:MLAB) FQ2 results: Revenues: $18.5M (+45.7%); COGS: $7.4M (+45.1%); Operating Expenses: $6.2M (+21.6%); Operating Income: $4.9M (+96.0%); Net Income: $3.1M (+63.2%); EPS: $0.84 (+55.6%); Quick Assets: $3.7M (-33.9%).

Health Net, Inc.(NYSE:HNT) Q3 results: Revenues: $3,789.9M (+36.6%); Operating Expenses: $3,767.1M (+41.3%); Operating Income: $22.7M (-79.1%); Net Loss: ($8.9M) (-113.3%); Loss Per Share: ($0.11) (-113.3%); Quick Assets: $2779.4M (+22.6%); CF Ops: $588M (+94.6%).

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Q3 results: Revenues: $17.4M (+123.1%); COGS: $3.1M (+14.8%); R&D Expense: $0.9M (+80.0%); SG&A: $4.1M (+17.1%); Operating Income: $8.2M (+811.1%); Net Income: $6.7M (+458.3%); EPS: $0.59 (+353.8%); Quick Assets: $35.1M (+219.1%).